In short
Podcast Notes: CNBC's "Fast Money" - Episode Summary (9/12/24)
Overview Podcast Title: CNBC's "Fast Money" Host: Melissa Lee Air Time: Weeknights at 5 PM ET on CNBC Episode Title: Nvidia CEO Weighs In On White House Tech Meeting… And An Ominous Sign For Retail Episode Description: Discussion on AI energy usage, Nvidia's chip production, and predictions for holiday retail sales.
---
Key Segments
- Jensen Huang's Insights from the White House Meeting
- Participants: Nvidia's Jensen Huang, executives from Google, Microsoft, Anthropic, and OpenAI.
- Focus: Discussion centered on AI's energy usage and boosting public-private cooperation to enhance AI infrastructure in the U.S.
- Key Points from Huang:
- AI models consume significant energy during training but can lead to energy savings during operational use.
- Nvidia is in full production of its new Blackwell chips, which are crucial for AI infrastructure.
- Huang emphasized the need for financial backing for AI infrastructure development in the U.S.
- McDonald’s $5 Value Meal Extension
- Announcement: McDonald's will extend its $5 value meal deal through December at most locations.
- Rationale:
- The fast-food chain is trying to attract customers amidst high prices.
- Approximately 80% of local markets will continue offering the deal, reflecting a competitive strategy in the fast-food industry.
- Competition: Other chains like Burger King and Taco Bell are also adapting their pricing strategies in response to consumer demand for value.
- Moderna's Disappointing Guidance and Stock Reaction
- Situation: Moderna’s stock hit a 10-month low after the company provided weak guidance during its R&D day.
- Concerns:
- Investors are worried about the effectiveness of their weight loss pill and the potential side effects.
- Moderna announced plans to cut approximately $1.1 billion in expenses by 2027.
- Holiday Sales Forecast
- Deloitte Report: Predictions suggest a weak holiday sales growth of only 2.3% to 3.3%, the lowest since 2018.
- Discussion Among Analysts:
- Concerns over consumer spending amidst economic pressures but some analysts remain optimistic if economic conditions improve.
- Discussion on how significant discounts may impact retailer margins.
---
Key Insights and Predictions
- Nvidia's Position: The market is optimistic about Nvidia due to its leadership in AI technology and the urgency for its new chip production.
- Consumer Behavior: Analysts indicated a potential shift in consumer spending patterns, particularly towards value-based offerings in fast food and retail.
- Retail Sector Outlook: There remains skepticism about overall consumer spending as economic pressures persist, but some analysts believe that improved macroeconomic conditions could benefit retailers during the holiday season.
---
Panelist Insights
- Guy Adami: Expressed skepticism about Nvidia's valuation despite positive market movements, suggesting caution.
- Tim Seymour: Highlighted the importance of macroeconomic factors and argued that they could favor tech stocks in the current climate.
- Dan Nathan: Shared insights from Goldman Sachs' Communicopia Conference, noting mixed sentiment among institutional investors regarding Nvidia.
Final Trades
- Dan Nathan: Google
- Steve Grasso: Walmart
- Guy Adami: Gilead
---
Conclusion This episode of "Fast Money" provided crucial insights into the current state of the tech and retail sectors, highlighting Nvidia's advancements in AI and the challenges facing retailers as they prepare for the holiday season. The discussions emphasized the importance of market conditions and consumer behavior as key factors to watch in the coming months.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:01Live from the Nasdaq market state in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. Jensen Huang on the record. All the headlines from the exclusive CNBC interview with the NVIDIA CEO straight from his meeting at the White House. What he had to say about the rollout of their highly anticipated Blackwell chip. Plus, happier meals. McDonald's extending its five dollar value menu until at least the end of the year. What it'll mean for the company and how the competition stacks up. Plus, a Moderna meltdown. The guidance that sends shares to 10-month lows.
0:30Roach's weight loss pill raises some concerns over potential side effects. And is it too early to start the countdown to Christmas? Sure. Never, never, Guy Adami. The latest read on how holiday sales could pan out this year. I'm Melissa Lee coming to you live from the studio of Vietta Nasdaq. On the desk tonight, Tim Seymour, Guy Adami, Dan Nathan, and Steve Grasso. We start off with two big stories tonight. First, McDonald's extending its$5 value meal from the summer into December at most of its locations. The fast food chain looking to win back customers with discounts as diners grapple with persistently high prices.
1:04But we start off with NVIDIA CEO Jensen Huang and other top tech execs meeting with White House officials to discuss AI's energy use. Our own Megan Casella spoke with Huang in an exclusive interview right after that meeting. Megan. Hey, Melissa, that's right. So Huang and other AI executives from Google, Microsoft, Anthropic, OpenAI, they were all at the White House today to talk energy needs for AI. The goal was boosting public-private cooperation here to make sure that energy and then some technical issues like workforce and permitting, that they aren't blocking the build-out of AI infrastructure in the U.S.
1:35When we caught up with Wong after the meeting, he talked about the new industrial revolution that we're in with AI. On energy specifically, he said that while AI models take a lot of energy to train, they can also save a lot of energy once they are in use. We also spoke about the company's Blackwell chips. As you mentioned, listen to this. And so each generation reduces energy consumption, increases performance, reduces cost. And so we're in a hurry to get to Blackwell. We're full volume production of Blackwell. And every company in the world is chomping at the bit for us to ship it. Melissa, I also asked if there was enough money behind AI infrastructure at this point.
2:16And he sort of said, well, if the U.S. doesn't have the money, then he doesn't see any other nation that could take better advantage of this technology. Melissa? All right, Megan, thank you. Megan Casella and NVIDIA has had a nice couple of days here, Guy, and resumed its upward move. Yeah, yesterday we talked about the powerful reversal in the S &P 500. We said, you know, if you see it to the downside, we're going to talk about it. Well, we saw it to the upside yesterday. Steve's been talking about sort of if it got back through 110 and a half, I think that's, I want to say the 100-day moving average.
2:44I might be off by a hair, but, you know, it would be a net place to sort of get back in on the long side. And he's probably want to be in spot on. Jensen's telling a great story. People are excited again. The fact that it held those lows like a champ is encouraging, and it sets it up well. With that said, you know I'm still a bit of a skeptic in terms of a number of different things, not least with valuation. And, you know, I think that SMCI story is still out there in the ether. But right now, technically, it looks pretty good. It's been almost an 11 percent move in the Semiconductors Index, the Sox, the Philly Sox, whatever you want to look at the SMH in four days.
3:18So that's the part of the market that if you are looking for the market itself to pick up and go again, you need to have you need to have that. And I would argue that the CPI number this week and some of the other supporting inflation data is very mega tech friendly. So if it's a little bit hotter, if it's a little less pressure on the Fed, that's actually very good for tech. And I would go back again. I do this a lot. I feel like lately, because that July CPI number, if you look at the underperformance of semis and mega cap tech, a lot of it happened that day, a day when you thought, boy, this gets the Fed out of the way, because, in fact, it was a great inflation number, meaning there was no inflation or there was less inflation.
3:55So it's fascinating. The intraday move from yesterday, guys talking about this is a powerful move. It's 190 S &P points. And it's actually a case where it's largely been tech led, even though I know today you had that breadth. So is the macro enough? And I'll go to you, Dan Nathan. Since you're in San Francisco, you're at the Goldman Sachs Communicopia Conference where Huang spoke just yesterday. Is that enough to offset sort of the waning enthusiasm, it seems, for AI in general, NVIDIA specifically? Barron just had an article a couple of days ago citing how many shares institutions are selling.
4:29Fidelity reduced its stake by 19 percent. Citadel Advisors reduced its stake by 93 percent. T. Rowe, Bailey, Gifford, they all cut stakes as well. Yeah, it's interesting. I think the most controversial thing this week as it relates to NVIDIA is that Jensen Wang at the White House today not wearing the black leather jacket. And what is that saying about the future of this stock? No, I'm just kidding there. It is interesting, though. And I'll just say this as I think about like some of the commentary in and around the conference yesterday and the conversation that he had with David Solomon. I don't think there was that much new there.
5:02If anything, when you're talking about some of the customer demand and the tension that he spoke to about customers looking to get this Blackwell. So from here on out, the story is he just said they're in full production. It's just how much supply they're going to have for how much demand. I think the real story yesterday was the news from the information that Meta, one of their biggest customers of NVIDIA, is working on this 100 ,000 GPU cluster. And it just speaks to and using the H100. So the existing iteration of this GPU, that's what really got NVIDIA going yesterday. Just quickly on some of the commentary, I probably talked about 15 investors into your point, Mel.
5:41Those are large mutual fund complexes that are selling. But the hedge fund people are also kind of skeptical here from what I could take. That was almost nearly universal. That's in the near term until you hear more about use cases and ROI. And so when I look at the chart and I look at the price action, I see a series of lower highs. This might be kind of tapped out in the near term, in my opinion. And so from a technical basis, and then you take the selling by institutions, and then you take the selling by Jensen Wang, and you say to yourself, I don't think this thing is going to make a new high anytime soon.
6:16Grasso, how have you been trading NVIDIA lately? so it was back basically a guy you know talked about that 100 day moving average where i said i would rather not get back in until it was above that average and for me it was a buy above 110 but now that 100 day moving average is 112 not to get too confusing to the people watching but when you trade this much higher this quick you have to look at the other moving averages now so you got the 50 day is 117.75. If you're in it now, you're going to use that as you're out. That should be your stop loss because you've made money from 110 all the way back up to 120.
6:59Now you want to guard those gains. The macro is exceptional right now. The market is doing well. It feels like there's never going to be another down day, but we all know that down day is coming. September, worst day for semiconductors and worst day for the indices. So let's just see how we ride out these last two weeks. But I would keep a short leash on NVIDIA if you're long right now. How are you feeling about it, Tim? Does macro Trump waning AI enthusiasm? I think it does here. I think the Fed's always the most important. I think on a day when you're using the metaphor of the next industrial revolution outside of Washington, that's a metaphor that's for Washington.
7:40and it's not for Wall Street. I mean, we kind of know what's going on, and I don't think there's anything different that the street hasn't, frankly, priced in here. I think, though, NVIDIA still is so far ahead. I think the price action here has been such that clearly there are buyers of dips. But the question about growth, I would bring it back to today, and I realize jobless claims and continuing claims are like microscopic points that are very noisy on the course of judging the labor market, but they don't align with a job market that's printed the last couple payroll numbers on the first Friday of the month.
8:12And I think that's part of where, again, it's the environment that the macro for the market and for the Fed and for, sorry, guys, soft landing, you know, no landing, I believe, particularly by Goldilocks. This is, to me, also the part of the story that's allowed passive investors to pile in. And I think that, you know, today was one of those days. Eight minutes in the show. Yeah. Holiday shopping. Countdown to Christmas, which you love. We could get Hump Day in there, too, if it was yesterday. No, you can't. I've already exercised enough from yesterday's Mets victory. I'll say this quickly, though.
8:44You know, he's telling a great story, he being Jensen. I get it. And yesterday he mentioned how$5 you're going to get back for every dollar you spend. Right now, the best case scenario that I've seen has come from Walmart and Facebook in terms of their ability to monetize. Nobody else has really proven anything yet. So there's still a lot of hopium in this trade. And I think Steve's numbers continue to be spot on. And is anyone really going to give us that number? No. And there are other places that, again, we have tried to peripherally play AI. And the utility sector, I think, is, again, another one of these places where it's alive and well, whether it's WEC, whether it's Southern Co., whether it's NextEra.
9:20I mean, I think the utilities in terms of those that are best positioned and actually have a role in data center demand, that's been a great trade. All right. Meantime, McDonald's loving it. The fast food chain extending its value meal for a second time. The deal was originally slated to expire in August, but now will go until the end of the year for$5. Customers can get a McChicken or McDouble, four-piece chicken nuggets, fries, and a drink. Yuck. That's a lot of— Why yuck? Why yuck? Don't be a hater. America loves McDonald's. CNBC's Kate Rogers is more. Hey, Kate. Hey, Melissa. As you said, McDonald's will be extending that$5 value meal through December in most local markets.
9:56The company said now roughly 80 % of local markets are extending the meal deal, which, as you said, includes that McDouble or McChicken sandwich, small fries, four-piece nuggets, and a small drink, all for$5. Votes on this meal extending are still ongoing, so there's the potential to see additional participation from franchisees confirmed in the coming weeks. Joe Erlinger, president of McDonald's USA, said in a statement, quote, Together with our franchisees, we're committed to keeping our prices as affordable as possible, which is why we're doubling down with even more ways to save. Value, as we all know, has been a key focus and theme across the restaurant sector this summer, with companies from Burger King to McDonald's, even Starbucks, getting in on those$5 bundles to caption the attention of consumers.
10:36Starbucks had that pairings offer. That was for a limited time this summer. Burger King's runs through October. Taco Bell also has a$7 meal box that's available. After a challenging second quarter in July, McDonald's executives told restaurant operators and analysts post-earnings it would be refocusing on how to recapture consumers with deals as they push for an extension of the$5 meal platform. And as you said, now this is the second time that they've done that through the end of the year. Back over to you. Kate, in general, Once a player like McDonald's extends to December, is the pressure on for the rest to keep their value meals in place?
11:08Certainly. And I think, you know, in just about a month when earnings season kind of kicks off for the restaurant sector, we're going to find out, you know, who's really nailed it here and who's working in terms of the$5 platform really resonating. McDonald's did say earlier in the summer in a memo that we obtained that this was testing well with the low-income consumer, and that is the cohort that they were losing and really need to get back. So we'll see if it's working. All right, Kate, thank you. Kate Rogers in San Francisco. Let's bring in now Wedbush Securities, Nick Setien. Actually, we don't have Nick quite yet.
11:36Okay. But we will talk. I like Nick. I know you're disappointed. I am disappointed. We can do this here. We can do that for now. We're fine. Because it's been quite a bounce in shares of McDonald's. It's been an 18 % bounce, I think, in 35 some odd sessions. And if anyone is surprised that they extended this$5 meal is crazy. I mean, this is what they do. This is the program. And the sense is I'm getting from the analyst community, and we'll hear this from Nick soon enough, is to what extent are July and August same-store sales comps out there for the street too conservative? Plus, throw in, guy, you're a big Crocs wearer.
12:06Apparently, starting in two weeks, there's going to be a Crocs keychain's promotion in your Happy Meal, which many people believe is going to drive traffic. I know it's certainly going to get the Adami family there. You're going to get Happy Meal now? That's projection. That's the highest level of projection, number one. There's nothing wrong with, like, a Crocs keychain. It doesn't like a Happy Meal or a good keychain. Listen, you know my order at McDonald's. We've talked about this a number of times. What is it? Is it a cheeseburger? Five cheeseburgers, large fry, medium Coke. Five cheeseburgers?
12:31The pickles are fine. Come on. What do you mean, come on? What are you, 20? Come on. No. If you go back and look, this is one I actually think we did a good job. You know, in January it topped out. As it started to decline, we said, okay, you know what's in line? That October low. Put up a chart from last October. You see 245. Look at where we traded down to on July 1st. Look at where we held. The problem, of course, now is we're right back to those prior all-time highs. So now the stock needs to prove itself, which I think it will do in the earnings. I think they release third week of October, something like the week before Halloween.
13:04So I think you ride the momentum here in MCD. All right. Now let's bring in Wedbush Securities' Nick Setien for more. He covers the restaurant space. Nick, great to see you. Thanks for having me. When you heard that McDonald's was extending, did you get more optimistic about earnings and revenues for the year? Or what was your initial reaction? Because there's a sort of a give and a take, obviously. I mean, I would imagine that the margins would be thinner, but they would increase traffic. You know, it's not a surprise. I think it's not the perfect solution. They are working on a better solution that will probably come out in early 2025.
13:41So this is a stopgap measure until then. But, you know, certainly the context is that there's just been too much inflation in QSR, McDonald's, you know, over 40 percent versus 2019, grocery much less. So the third of the customers that are direct meal replacement, you know, they don't care what brand they're buying from. They just want the cheapest price. They move to grocery and convenience, and McDonald's has to, you know, regain some of that share. This is their answer. It's not a perfect answer, but it is a stopgap until they figure out a better answer, probably in, you know, one age 25. Has it always been the case that McDonald's customers aren't necessarily brand loyal, that they just wanted the value for their money?
14:22because that seems like a bigger problem. If there's not actually inherent loyalty to this particular brand or these particular meals, it's just how cheap can you get it? Then that's a very difficult field to compete in. I'd say about a third of the customers, if you think about that lower, the very low-income customer, the value menu customer, has always historically used McDonald's and other QSR peers as direct meal replacement. And that's always been the case. McDonald's has always been a value leader because of that. And they've always garnered success because of that. But Nick hates Tim. Sounds to me when I hear$5 meal and I hear extension, I hear that the drivers that you just talked about, I hear margin pressure.
15:04And I wonder what multiple you think about McDonald's in context. And maybe if you can compare that to maybe how you were thinking about that multiple two years ago or four years ago or even pre-COVID, because we know the world has changed in terms of those cost inputs, the labor cost inputs. That, to me, is where you get to with McDonald's, because I think the brands there, Crocs, Key Chains, or not. You know, remember, McDonald's is a primarily franchise concept. So at the end of the day, what you care about a lot more is the top line and the bottom line. And the franchisees are the ones that are dealing with the margin pressures.
15:39At the end of the day, investors, really, all we care about is the royalties. Now, they do have a company-owned portfolio, but it's a very small percentage of the overall system. Nick, I'm wondering, from your standpoint, when you take a look at sort of the macro backdrop, do you agree that the consumer will continue to face challenges the same that they're facing right now or increase challenges going to the end of the year? Because what this is implying in terms of extending that$5 value meal is that that is the case, So that is the macro backdrop that things won't improve necessarily for the consumer.
16:16You know, I'm pretty optimistic at the end of the day. You know, to me, this is more about just bringing pricing in line with grocery. If you remember, we had another price war back in 2016 and 2018. You know, we were in a recession back then. Right. It's just that we had another extended period of restaurant inflation led by labor inflation at the time. That was, you know, over and above grocery inflation. So you see these cycles from time to time. So to me, it's not necessarily that it's a consumer slowdown issue. It literally is just that in the near term, we've had some share shift away from QSR and McDonald's towards the grocery, particularly value grocery and convenience stores.
16:58And so McDonald's, to me, is, in my opinion, is doing the right thing by making sure that gap versus grocery is going back in line with what it has been historically. All right. Nick, great to see you. Thank you. Nick Zetian of Wedbush. So it's right sizing the pricing. They took a lot of price at the beginning of inflation. They got to give it back. They did. And they got they got penalized for it. And remember the commentary a couple of quarters ago. But then you look at the second quarter, they reported, I think, in July 29th or so, whenever it was. That seems to be the turn because it wasn't as bad as the street was looking for.
17:33Remember where the stock was at the time. Now I think the turn's in place. Now the momentum that they had four quarters ago seems to be back in McDonald's. And you could say stretched on valuation, but they always seem to figure it out. And I think that hiccup notwithstanding, they're in pretty firm footing right now. Steve? Yeah, to Tim's point, I'd be first worried about the margins on this. But when you look at the chart, the 50 moved up through the 100 day. It's not the golden cross, but it's positive. I think they could manage to hold on to share. But when I when I look at other names in the space, Brinker International blows away the entire quick serve place, a space.
18:15If I wanted to buy something and say, OK, can McDonald's go back to the old stand standby, the old guard? I think you're OK. If I want to make more money, I think I stay in EAT. All right. Coming up, Adobe on the move after its latest earnings report. The numbers behind the after hours action is next. Plus, investors sprinting out of Moderna shares after its latest guidance raised concerns. The headlines hammering the stock right after this. This is Fast Money with Melissa Lee right here on CNBC.
18:58Welcome back to Fast Money. We've got an earnings alert on Adobe, the software company's stock plummeting after disappointing Q4 guidance. The CEO just spoke exclusively to CNBC in the last hour. And our Julia Borson joins us now with a recap of the interview and the breakdown of the results. Julia. Hey, that's right, Melissa. Shares are now down about 10 percent in after hours after Adobe's fourth quarter revenue guidance missed estimates. The company forecasting revenue $5.5 to$5.55 billion, but slightly lower than the street expected. Now, despite that disappointing outlook, when CEO Shantanu Narayan joined closing Bell overtime in the last hour, he said he feels good about Adobe's future.
19:36Most people would characterize the economy as either, you know, a little bit slow or stable. We have seen stability in our business. I think we're all probably looking forward to seeing what both the Fed says as well as what happens in the elections. But if you look at our fundamental long term trends and the ability for technology to continue to drive even more value, we're bullish. Narayan also says he's bullish in the company's AI initiative, saying he does not think there's another company that's demonstrated the amount of innovation that Adobe's AI assistant has so far. But John, I'm sorry, excuse me, Melissa C shares now down 10 percent.
20:17And Shantan Narayan did that interview with our colleague, John Ford. Julia, thank you. Julia Borsten. Dan Nathan, I go to you on this, this 10 percent decline. What do you make of that? Well, really interesting. And I also think it's fascinating that in that interview he speaks of the macro. And, you know, like that's something that you wouldn't expect for like a creative suite of products right now, that it would probably weigh too much on that. You know, last summer we are spending a lot of time. This is summer of 23, kind of figuring out who is going to be the early beneficiaries of generative AI.
20:47You would have thought that SaaS sort of companies like this would have done that. They announced this Firefly product. This is generative AI across their creative suites and Adobe Acrobat and the like here. And the market has just not appreciated whatsoever. So when you have a miss like they've just guided to on net new digital media, this is ARR, You know, that's the sort of thing that investors are just not going to be that patient about right there. So is it deservedly down 10 percent? I'm not sure. But if you think of 2025 and you think of earnings estimates expected to be up 13 percent, sales estimates to be up about 11 percent.
21:22This is an 89 percent gross margin company, which is fabulous. Right. But they're not demonstrating the sort of growth that justifies nearly a 29 multiple on 2025 numbers. So, again, down 10 percent seems a little curious. The stock was down about 2 % on the year, really underperforming many other names that have been talking a big Gen. AI story for the last year or so. I feel like often in the after-hour session on the back of Adobe's results, there is a sharp decline in the shares. And then what – I'm in your brain tonight. You're channeling my – It's crazy. But it's true. We've seen it quarter after quarter.
21:57Three out of the last four, they've dropped a donut. A what? Dropped a donut. That sounds disgusting, Tennessee. It's fine. I mean, I don't know about dropping donuts on Sam &C's fast money. This time, is it warranted? To the extent that it's sold, no, I don't think it is. But I'll tell you now, when you guide lower in this environment with that valuation, that's what's going to happen. With that said, take a look at where it traded down to on August 5th. I think you got down to about$509 or so. That's your crosshairs. That's where you get back into stock because, yes, it's expensive. A stock that probably made its all-time high, I want to say, in 2021.
22:31This is a fabulous company with, as Dan mentioned, incredible margins. You're trying to find a place to buy this stock, and I think it comes in the form of 510. And I would lean towards the buy, because that guide, which is, those numbers were fine. It was the guide that was, I think, about 15 million light on 550. So what's that, 3.5 %? I mean, I guess, you know, it depends on how you believe any relative miss how important it is. I don't think that's a game changer for a company that I think was starting to put it back together. So I think this is weakness you're buying. There's a lot more fast money to come.
23:03Here's what's coming up next.
Read the full transcript
23:30Could be the worst year since 2018. You're watching Fast Money live from the NASDAQ market site in Times Square. We're back right after this.
23:47Welcome back to Fast Money. We've got a buzzkill on Moderna. Shares plunging after the company gave disappointing guidance at its latest R &D day. Moderna says it plans to cut around$1.1 billion in expenses by 2027 and get 10 products approved in that same time frame. It also slashed its R &D budget, saying it will pause or scrap research on projects such as its latent virus portfolio. Moderna also lowering its revenue outlook for next year and said it should break even in 2028. Steve Grasso. It's really hard to trim your R &D and then launch 10 new products. That's why the market's probably not treating it favorably.
24:25And I don't see how it could be. People are not lining up to take the shots anymore. You have a stock that's trading back to the October 2020 level. But it just had a death cross. I'm a firm believer when you see a death cross, the downside is nearly played out. So if you're looking for a little bit of a bounce here, maybe you want to roll the dice on it and just keep it close to the vest. All right. Meantime, take a look at shares of Summit Therapeutics. That company topping the tape today up another 20 percent. This is after the company said it sold more than 10 million shares of stock, raising$235 million from insiders and institutional investors.
25:05The announcement coming after our interview with the co-CEOs last night, shares are up nearly 120 percent just this week on positive trial results for its lung cancer drug, which would compete with Merck's Keytruda. And in yesterday's interview, they did say that the profile should be similar to Keytruda in terms of the applications for the drug, the uses of. And right now, Keytruda treats at least 18 different kinds of cancer. And with more indications probably coming, comes off patent, I think, in 2028. If this is going to compete at that level, I mean, a$27.40 stock, you might be able to move the decimal place at some point because that's what we're looking at in terms of total addressable market.
25:45if they get it right. So you want to play binary outcomes. This is it. And when stocks trade that well off secondaries, that is a huge tell. Yeah. And the sense is we've had this conversation when other people have had these kind of moves or we've suggested maybe it's a great time to do a secondary. But the sense is always, can they do it alone? Are they someone that's ripe for a takeout? Again, I won't get into that. They're obviously going to say we can do it alone when this is what we're going to do. It's what they said last night. Yeah, exactly. But I think it's still a case where this is a company where intrinsically people see a lot of value.
26:16That Moderna output, by the way, the profitability pushed out two years. Very disappointing for a company that at one point had a lot of cash on their balance sheet, and people kind of did the valuation in terms of the total percentage of cash on the balance sheet. So how about Merki? 114, I think it closed today. Obviously, there are concerns around Keytruda, but other drugs as well. What's going to happen? They're going to have to make an acquisition. Not that I know anything whatsoever, but if you think about what just happened with Summit specifically, But then think about the GLP-1 and the head start that Lilly has and Novo has.
26:45It's going to force Mark's hand at some point, and they will do something. I still think at$114, it's cheap with all the things, all the headwinds, all the Keytruda headwinds. This is a stock that I think you buy here and not sell. All right. Coming up, Roach shares slimming down after disappointing obesity drug data. The struggles, the side effects, and the next steps for the Pharma giant. That's next. Plus, the holiday shopping season is nearly upon us. Seriously. But analysts are expecting nothing but coal in retailer stockings this year. The chilly forecast. Oh, boy. Oh, man, Mel. Oh, boy.
27:17Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money Podcast. We're back right after this.
27:33Welcome back to Fast Money Stocks, rallying for the second day running. The Dow jumping 219 points, the S &P gaining three quarters of a percent, locking in a four-day winning streak. And the Nasdaq surging 1 % as tech continues to rebound. Meanwhile, Kroger shares ripping higher after the grocery chain beat expectations before the bell. The company said customer visits were up and that delivery sales were 17 % higher than last year. And R8 shares surging after hours on a big earnings beat. The high-end home retailer also issuing upbeat guidance into 2024. Tim, I know you're familiar with their offerings.
28:07Yeah, I am familiar with the offerings and I'm familiar with the stock. I actually own the stock. And I think the idea here is we know that there's very mixed trends in terms of home furnishings. We know that they are certainly at the premium end. We also know that this was about essentially resetting, right-sizing expectations. I think they cleared the deck. I think this was really about where people understand to be that inflection on where I think they're going to start to build again. Remember, they've done a decent job about not having to be overly promotional because that's not what they do.
28:34I think the stock's going to continue to be extremely volatile. I think this space, and I've been somewhat critical of the WSM play, despite some of the products that they have there that seem to be selling off the shelf. I think you have to be cautious in this space. But RH, I think on valuation, nine times EBITDA, you're paid to stay. By the way, I think I misspoke. They increased guidance into 2025, not just the end of the year, which is even more bullish. I mean, to be able to forecast into next year is pretty amazing. And let's go to Kroger real quick. With a company with probably a bullseye on their back in terms of, you know, price gouging and all the things we've heard from both sides of the aisle.
29:14I'll say this. That was a pretty good quarter. And evaluation is still compelling. And within a whisper of a prior all-time high that we made a couple years ago, margins improving. Seemingly, their business is being run better. I think you still own Kroger's here. Well, Christmas. Yeah. Maybe three months away, but it's never too early to break out the countdown clock for the holidays. Get that. 130 days, six hours, 22 minutes and seven seconds and counting until Christmas. We might already be getting some signs, though, that the Grinch is going to steal Christmas this year. A Deloitte report out today predicts the weakest gain in holiday sales since 2018.
29:54That is worse than at any time during the pandemic. spending expected to rise between 2.3 % and 3.3 % between November and January. Last year, sales grew by 4.3 % in that period. Dan, are you worried about retailers and Christmas? You're worried about retailers even without a bad Christmas. Well, let's think about it this way. Guy's been saying this on Fast Money for nearly 17 years, that consumer confidence is really just an overlay of the S &P 500. Well, last I checked, the S &P 500 is within a couple percent of all-time highs. It's up 17 percent on the year. If we get rate cuts this year where it looks like it's going to do, the CME FedWatch tool is what pricing in maybe 100 basis points of cuts in the next few months or so.
30:37You think about the wealth effect from the stock market and possibly from housing. Look where the XHB is. And you say to yourself, maybe four percent is very achievable or maybe higher. You know, so I just don't know. You know, I think it it probably makes sense to not be too cautious on that because if things can hang in there, then consumers are going to feel pretty decent about spending around Christmas. The other thing that Guy Adami has been saying for 17 years, among the myriad of things that he's been saying for 17 years, but specifically pertaining to retail and spending, is that you never underestimate the American consumer, Steve Grasso.
31:12So do you think, you know, in the end, we pull it out, we spend, spend, spend for our loved ones? Well, if you think about it, to Dan's point, if rates start coming down, then you're going to, in effect, you'll probably have more home equity lines of credit coming out. And the consumer probably gets another lifeline, even though it feels as though they've already ran through enough of these lifelines. But when I think of what the consumer is going through right now, I think of Walmart. And Walmart, you could buy your groceries. You could buy your clothes. Tim, no laughing. and you could buy your Christmas gifts.
31:53It's the everything for everyone. Their digital play is like no other at this point. Guy talked about it in the top of the show saying that they've been able to really leverage AI. So I think this will benefit them, but I think the consumer will be just fine if rates come down. Yeah, I mean, there's no question I'm going to Walmart for my Suvets. And I think you have a case here where I kind of like, I think discretionary is under pressure. Everything we've been saying about the consumer and consumer credit and where we might be going. I recognize that the market, like the Adami-isms, we've now quoted two tonight, which is impressive.
32:28There's a lot. Good for him for establishing that lane there. But I think we have a dynamic here where I think discretionary is going to be under pressure. Isn't that the narrative we're having with both consumer credit and where people one day were worried about a hard landing? I mean, the point is, I don't think a lot of these retailers are priced for that. And I think, if anything, that trend gets worse. Before we go, Mel, I have to say, Skye, we have time, right? No, not really, but you've already started, so go ahead. These Friday shows, we have a lot of time. Like the Wicked Witch of the West, the Grinch is one of the most misunderstood characters, maybe in cinema history.
33:04No, no, no. This was just a misunderstood person who was ostracized by society that had a big heart, that needed to see what happened there at the end for him to fully embrace it. So let's not start saying Grinch because we're doing him a disservice. Yeah. And all the Grinch is out there. It's only half of the story, right? Kind of like the Abominable Snowman, too. He was a nice guy by the end. Right. He's putting up stars on top of Christmas. Winch of Warlock. That was his new job in the end. Yeah. Wow. We've really turned a corner here. Coming up, Dan Nathan's been living up out west from driverless cars to NBA stars and the latest temperature check on the AI trade.
33:38He'll give us a full report next, plus the skinny on some disappointing obesity drug trials out of Roach. We will dig into the results when Fast Money returns.
33:54Welcome back to Fast Money. Switzerland traded shares of Roach closing 2 % lower today after the company gave updates on its oral obesity drug late Wednesday. The company disclosing that all 25 participants in a phase one trial experienced mild to moderate side effects and that the mean weight loss of 6.1 % at four weeks was actually contained to six patients in the best-performing trial cohort. Roach's U.S.-traded ADR, meantime, closing almost 4 % higher. For more, we are joined by Manu Chakravarti, Roach's global head of cardiovascular, renal, and metabolism, metabolism, excuse me, product development.
34:26Manu, great to have you with us. Thanks, Melissa, for having me back again. I wanted to first talk about your oral offering since that's the latest data, and we also got the recent data from Novo as well. Can you talk us through why there was so much nausea that you saw in terms of the adverse events for this group? And tell us exactly how you can sort of reduce that, because reducing it would mean probably slower titration or more slowly increasing the dosing, which would then stretch out the time frame for the weight loss. Yeah, so let me just take it back here for a second. And so the way that this study was actually conducted, and which is the whole point of doing a study like this, is to actually, what we say, you know, fail fast.
35:15And so you go a little bit quicker in the titration scheme that you normally do. So we want to go actually purposefully quickly because you have a short period of time. It's usually four weeks. That is a typical time that phase one studies are typically done. So you want to try to get as much information as you can as quickly as possible. And so it's sort of an artificial system, if you will. And the whole point of that is to see if you have any unexpected safety or unexpected toxicity that you don't anticipate of the class. So since we knew a lot about the mechanism, which is an oral GLP-1 agonist, we knew that, of course, we're going to see GI-related tolerability.
35:55But the key is to see if there was anything unexpected. So the nausea rate that we saw is very much in line with what you typically see with any other GLP-1 agonist, dual agonist, triple agonist, even in the amylin and GLP-1 that you just mentioned, the amycretin from NOVO. They're all pretty much when you line it up, they're all in the same category for this stage of development. The problem is that, you know, people sort of conflate phase one studies with phase three results, which, of course, is going to make the phase one results look really bad. But again, if you actually line up all these early studies of all these other compounds, they're all exactly the same.
36:34So nothing unexpected that we saw in the safety, which actually gives us a lot of confidence to move actually the program forward into phase two, which is exactly what we intend to do in 2025. five. How about the six patients part of this whole thing? I mean, that's another part that investors are concerned about. And so, you know, when you're thinking about the next trial, how are you thinking in terms of the size? How are you thinking in terms of timing and titration as well, dosing? So that's a thanks for the opportunity to clarify that. So when we do this study, we actually split up the groups into the cohorts of six, which is, again, a very typical type of sample size that you have.
37:12So the data, you have to look at it from the totality, right? So in each cohort, there were six patients along with the placebo. Placebo response was about 1.2%, which tells you that it's exactly in line with what others have shown. So the placebo effect is very much consistent with the class, if you will, of the weight loss category. And then if you look at the cohorts 2 and 3, the cohort 2, which was 120 milligrams, titrated a little bit quickly at 5.8%. And then you have the same dose titrated a little bit slower, which is cohort three, which had 7.3%. So when you actually look at the totality of the data, even if you don't believe the six, you know, 7.3 % with six people, you look at the totality, you're seeing the weight loss very much in, you know, with a very positive signal relative to the placebo.
37:58So that is, again, a very typical size of the study. Again, if you look up all of the other studies, you know, at the same stage of development, they're all six to nine people. So in regarding to your question about the titration, so in fact, in the same study, not only did we show the replication of weight loss between two different cohorts, which is really reassuring, but actually, when you actually look at the slower titration group, the cohort three, that actually had more weight loss. So this notion of slowing down titration is going to worsen efficacy. I'm not sure that's really justified because, you know, our data from 996, as well as from our injectable, which was the CT388, both of them actually showed very similar trajectories, even when you slowed down the titration.
38:43So we don't anticipate efficacy to be impacted. In fact, if anything, when we slow down the titration, we would expect the tolerability to be even further improved. I guess the bottom line question, Manu, for people watching this space and particularly interested in the oral offerings is that, you I know you're saying if you line up all these studies, well, if we line up even your study, Phase 1, versus Amicretin, which is Novo's oral offering, Phase 1, Novo's offering looks superior according to a lot of the analysts that I've spoken to. And I'm just wondering, you know, and so some people are saying, you know, given that Lily is already working on an oral that's more advanced in terms of the phase number it's in, given that there is also a Viking Therapeutics offering that looks promising, where does your oral offering fit into this very crowded landscape at this point?
39:29So first and foremost, our molecule is a truly synthetic oral agonist, meaning it's not a peptide that's converted into an oral formulation. Right. So it's truly oral in that sense. And, you know, just to take one step back, you know, just to provide a little bit of context here of how hard it is to actually come up with a small molecule, truly oral molecule. It's incredibly hard. And that's why the field has really taken a long time. So all the molecules you just mentioned, generally like the Viking molecule, the amicretins, etc., are peptides that are converted to oral. 996 is one of the very few molecules, if at all any, that actually has passed through the gauntlet of how hard it is to get through.
40:10The first one is liver tox, right? I mean, many, many compounds have failed because of liver tox. We don't see a liver injury signal. Preclinical studies clearly show that any of the reactive species that's there is not present in our studies. High tox margins. We have that. You have, of course, you know, the question of whether the molecule is truly once daily. Right. And so that's another very important distinction is that, you know, we have a truly once daily molecule because of the pharmacokinetic properties. So I'm not sure it's fair to compare all of these in the same bucket. Okay. Manu, great to see you again.
40:46Thanks for your time. Sure. Thanks for having me. Coming up, Dan Nathan's been very busy on the West Coast this week. his boots on the ground report on the AI trade and self-driving taxis. Next, more Fast Money in 2.
41:06Welcome back to Fast Money. Our Dan Nathan has been out in San Francisco and Los Angeles this week, getting an up-close and personal look at everything from self-driving cars to investor sentiment around the AI trade. On our early show call today, he talked about his experience riding around San Francisco in a robo-taxi. So, Dan, we wanted you to do a little show and tell, please. Yeah, I mean, listen, it's a fascinating experience. The future is here. You know, we know that Elon Musk is going to roll out a lot of news about the robo-taxi event on October 10th. But look at what Waymo is doing here.
41:36These are really nice cars. These are, you know, they're clean. They're fast as far as the wait times relative to Uber. And they're cheaper. And so, to me, I just think this is really interesting. The question is, does this scale, right? All that technology, those very nice cars, who knows right now, but it's a great experience. I really enjoyed it, and I will tell you that if it gets to New York City, I will be using this over Uber every day of the week. Well, part of the story, though, Dan, which you mentioned on the call, is that the cars that they are using are very, very, very high-end luxury cars that you normally would not have in any form in New York City in terms of a ride hailing, right?
42:14I mean, how much of it was that, that it was a Jaguar? No, I mean, listen, they're very clean. It's not too different than the way that Tesla rolled out their first EVs. They went really high end. They wanted to get mass adoption or at least have this first mover advantage. And I think that's what they're doing in a town like San Francisco where people understand this technology. Right. All right. Up next, final trades.
42:46Time for the final trade. Dan Nathan. Yeah, Google. Steve. Walmart.
42:56Baba. Ho, ho, ho. Guys. I mean, they said, they must have said one word. Quick, quick. I know. Now we have all this time. Oh, Gilead. Thanks for watching Fast Money. See you back here tomorrow. Mad Money with Jim Cramer starts right now. All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.
43:32Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.
From the publisher
Top tech execs meeting with White House officials to discuss the future of AI energy usage. What the Nvidia CEO had to say about production, chip delays, and more. Plus Not so jolly tidings ahead of the Christmas season, as a new report point to weak sales. What it says about the consumer, and the retailers that could be seeing a lump of coal this season.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
